Barclays PLC Takes Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Barclays PLC acquired a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 54,886 shares of the company's stock, valued at approximately $731,000. Barclays PLC owned 0.21% of Eton Pharmaceuticals as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ETON. Cannell Capital LLC bought a new stake in Eton Pharmaceuticals in the 4th quarter valued at about $5,079,000. Geode Capital Management LLC raised its holdings in shares of Eton Pharmaceuticals by 13.5% during the third quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock valued at $1,637,000 after buying an additional 32,365 shares during the last quarter. Aristides Capital LLC boosted its position in shares of Eton Pharmaceuticals by 20.8% during the fourth quarter. Aristides Capital LLC now owns 241,587 shares of the company's stock worth $3,218,000 after buying an additional 41,587 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Eton Pharmaceuticals by 230.5% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock worth $2,862,000 after buying an additional 149,864 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in Eton Pharmaceuticals by 131.5% in the 4th quarter. Renaissance Technologies LLC now owns 193,100 shares of the company's stock valued at $2,572,000 after acquiring an additional 109,700 shares during the period. Institutional investors own 27.86% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ETON shares. B. Riley reissued a "buy" rating and issued a $24.00 price target (up previously from $21.00) on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th. Craig Hallum boosted their price objective on Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a "buy" rating in a research note on Wednesday, March 19th. Finally, HC Wainwright reiterated a "buy" rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th.

Eton Pharmaceuticals Stock Performance

Eton Pharmaceuticals stock opened at $16.60 on Wednesday. The firm has a market cap of $445.07 million, a price-to-earnings ratio of -75.44 and a beta of 1.22. Eton Pharmaceuticals, Inc. has a 1 year low of $3.18 and a 1 year high of $18.41. The firm's 50 day moving average price is $14.34 and its two-hundred day moving average price is $13.41.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). The company had revenue of $11.65 million for the quarter, compared to analyst estimates of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, equities analysts predict that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

Want to see what other hedge funds are holding ETON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.